Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas

Int J Dermatol. 2024 Oct;63(10):e255-e258. doi: 10.1111/ijd.17400. Epub 2024 Jul 25.
No abstract available

Keywords: anti‐IL23; biologics; difficult‐to‐treat area; guselkumab; psoriasis; real‐world data.

Publication types

  • Letter